Skip to main content

Silexion Therapeutics Corp

SLXN
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0002022416

No open-market purchases or sales by Silexion Therapeutics Corp insiders were filed in the last 90 days; 6 institutions reported holding it in 13F filings for Q2 2026, worth $42.5K in total; no superinvestor holds it.

Other share classesSLXNW

13F holders, Q1 2025

Institutional positions in Silexion Therapeutics Corp as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
5
+2 vs. Q4 2024
Shares held
236.2K
+96.0K (+68.5%) vs. Q4 2024
Total value
$259.8K
−$21.0K (−7.5%) vs. Q4 2024
New holders
3
1 more added
Sold out
1
0 more reduced

Compare with Q4 2024: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting SLXN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ1 2025: 5 institutions
Q1 2021: 0 institutionsQ2 2021: 0 institutionsQ3 2021: 0 institutionsQ4 2021: 0 institutionsQ1 2022: 0 institutionsQ2 2022: 0 institutionsQ3 2022: 0 institutionsQ4 2022: 0 institutionsQ1 2023: 0 institutionsQ2 2023: 0 institutionsQ3 2023: 0 institutionsQ4 2023: 0 institutionsQ1 2024: 0 institutionsQ2 2024: 0 institutionsQ3 2024: 5 institutionsQ4 2024: 3 institutionsQ1 2025: 5 institutionsQ2 2025: 8 institutionsQ3 2025: 4 institutionsQ4 2025: 6 institutionsQ1 2026: 7 institutionsQ2 2026: 6 institutions
Value heldQ1 2025: $259.8K
Q1 2021: $0Q2 2021: $0Q3 2021: $0Q4 2021: $0Q1 2022: $0Q2 2022: $0Q3 2022: $0Q4 2022: $0Q1 2023: $0Q2 2023: $0Q3 2023: $0Q4 2023: $0Q1 2024: $0Q2 2024: $0Q3 2024: $612.8KQ4 2024: $280.8KQ1 2025: $259.8KQ2 2025: $258.1KQ3 2025: $17.3KQ4 2025: $35.2KQ1 2026: $46.7KQ2 2026: $42.5K
Institutions holding SLXN and their total value by quarter
QuarterHoldersValue
Q2 20266$42.5K
Q1 20267$46.7K
Q4 20256$35.2K
Q3 20254$17.3K
Q2 20258$258.1K
Q1 20255$259.8K
Q4 20243$280.8K
Q3 20245$612.8K
Q2 20240$0
Q1 20240$0
Q4 20230$0
Q3 20230$0
Q2 20230$0
Q1 20230$0
Q4 20220$0
Q3 20220$0
Q2 20220$0
Q1 20220$0
Q4 20210$0
Q3 20210$0
Q2 20210$0
Q1 20210$0

Institutions, Q1 2025

Shares, value and share of portfolio for each institution holding Silexion Therapeutics Corp; share changes are against Q4 2024.

Institutions holding SLXN in Q1 2025
InstitutionSharesValue% of portfolioChange in sharesAction
Wildcat Capital Management, LLC113,428$124.8K0.07%00.0%Unchanged
UBS Group AG72,874$80.2K0.00%+58,020+390.6%Added
Meyer Handelman Co32,967$36.3K0.00%+32,967New
SBI Securities Co., Ltd.16,411$18.1K0.00%+16,411New
Bank of America Corp500$5500.00%+500New
HRT Financial LP0$00.00%−11,887−100.0%Sold out